Diabetes and Heart Disease

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Risk Assessment of Type 2 Diabetes in Pharmacies

Condition:   Type2 Diabetes
Intervention:   Other: Diabetes risk assessment service in Norwegian community pharmacies
Sponsor:   University of Bergen
Active, not recruiting

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo;   Drug: PF-06882961
Sponsor:   Pfizer
Completed

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MEDI0382;   Drug: Placebo
Sponsor:   MedImmune LLC
Completed

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Miami
Completed

Episodic to Real-Time Care in Diabetes Self-Management

Condition:   Diabetes Mellitus, Type II
Intervention:   Behavioral: Type 2 Diabetes Self-Management
Sponsor:   Duke University
Enrolling by invitation

Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy

Condition:   Type 2 Diabetes
Interventions:   Other: 24-hour intervention with multiple daily injections;   Other: 24-hour intervention with closed-loop strategy;   Drug: Insulin;   Device: Insulin pump Accu-Chek Combo;   Device: Dexcom G4 Platinum
Sponsors:   Institut de Recherches Cliniques de Montreal;   Réseau de recherche en santé cardiométabolique, diabète et obésité
Completed

Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin;   Drug: Metformin;   Drug: Dapagliflozin
Sponsor:   Majianhua
Not yet recruiting

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Recruiting

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Drug: Metformin and Liraglutide
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Children's National Medical Center (CNMC)
Recruiting

The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine

Condition:   Type2 Diabetes
Intervention:   Diagnostic Test: Continuous Glucose Monitoring System
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting

Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Completed

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3209590;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: IDegLira;   Drug: insulin degludec;   Drug: Metformin;   Behavioral: Lifestyle Therapy
Sponsors:   Population Health Research Institute;   Novo Nordisk A/S
Recruiting

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY900014;   Drug: Insulin Lispro;   Drug: Insulin Glargine;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Tirzepatide
Sponsor:   Eli Lilly and Company
Recruiting

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: iGlarLixi;   Drug: Insulin Glargine;   Drug: Metformin;   Behavioral: Lifestyle therapy
Sponsors:   Population Health Research Institute;   Sanofi
Active, not recruiting

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TQ-F3083 capsule 5 mg;   Drug: TQ-F3083 capsule 10 mg;   Drug: TQ-F3083 blank analog capsule;   Drug: Linagliptin blank analog tablet;   Drug: Linagliptin tablet
Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Completed

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Completed

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo for Bexagliflozin;   Drug: Glimepiride;   Drug: Placebo for Glimepiride
Sponsor:   Theracos
Active, not recruiting

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: glucokinase activator;   Drug: Placebo
Sponsor:   PegBio Co., Ltd.
Not yet recruiting

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Vildagliptin;   Drug: Insulin;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Terminated

Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

Condition:   Type 2 Diabetes Treated With Insulin
Intervention:   Device: Livongo-Insulia Study App
Sponsors:   Livongo Health;   Voluntis;   Evidation Health
Recruiting

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide SAR439977;   Drug: Dulaglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: placebo
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: efpeglenatide (SAR439977);   Drug: placebo
Sponsor:   Sanofi
Recruiting

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: placebo;   Drug: metformin;   Drug: sulfonylurea
Sponsor:   Sanofi
Recruiting

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Metformin
Sponsor:   Sanofi
Completed

Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: insulin glargine (HOE901);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Subjects With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: glimepiride;   Drug: metformin;   Drug: placebo
Sponsor:   Sanofi
Active, not recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: placebo;   Drug: Metformin;   Drug: Sulfonylurea
Sponsor:   Sanofi
Completed

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Condition:   Heart Failure-Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Empagliflozin;   Drug: Placebo
Sponsor:   Sanofi
Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Sponsor:   Sanofi
Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo to vildagliptin;   Drug: vildagliptin;   Drug: Metformin
Sponsor:   Novartis Pharmaceuticals
Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Condition:   Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg;   Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Sponsor:   AstraZeneca
Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

Condition:   Type 2 Diabetes Mellitus-Chronic Kidney Disease Stage 3
Interventions:   Drug: Placebo;   Drug: Sotagliflozin (SAR439954)
Sponsor:   Sanofi
Active, not recruiting

A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

Condition:   Type 2 Diabetes Mellitus-Chronic Kidney Disease Stage 4
Interventions:   Drug: Placebo;   Drug: Sotagliflozin (SAR439954)
Sponsor:   Sanofi
Active, not recruiting

Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)

Condition:   Type2 Diabetes Mellitus
Interventions:   Behavioral: Patient and/or Family Member Intervention;   Behavioral: Certified Diabetes Educator Intervention;   Behavioral: Physician Intervention;   Behavioral: Front Desk Staff Intervention;   Behavioral: Nurse Intervention
Sponsors:   Georgia Institute of Technology;   Emory University
Not yet recruiting

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

Conditions:   IGT - Impaired Glucose Tolerance;   T2D
Interventions:   Diagnostic Test: Oral Glucose Tolerance Test;   Diagnostic Test: Hyperglycemic Clamp;   Diagnostic Test: Isoglycemic Intravenous Glucose Test;   Diagnostic Test: Hyperinsulinemic Euglycemic Clamp and 2H20
Sponsor:   Yale University
Recruiting

A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: TRADIANCE® Combination Tablets AP;   Drug: TRADIANCE® Combination Tablets BP
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec/liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Dapagliflozin 10 MG
Sponsors:   Uppsala University;   Uppsala University Hospital;   Swedish Healthcare Regions;   Swedish National Board of Health and Welfare;   The Swedish National Diabetes Register
Recruiting

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Lixisenatide (AVE0010);   Drug: Metformin
Sponsor:   Sanofi
Recruiting

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
Sponsor:   Sanofi
Recruiting

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Completed

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: bimagrumab;   Other: placebo
Sponsor:   Novartis Pharmaceuticals
Completed

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: EGT0001442;   Drug: Placebo capsules to match EGT0001442
Sponsor:   Theracos
Completed

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

Conditions:   Obesity;   Overweight;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Progressive vs. Non-progressive Water-based Aerobic Training on Type 2 Diabetes Control: a Randomized Clinical Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: Progressive water-based aerobic training;   Other: Non-progressive aerobic training
Sponsors:   Federal University of Rio Grande do Sul;   Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Not yet recruiting

Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Text messaging
Sponsors:   University of Nebraska Lincoln;   The Methodist Hospital System
Completed

Vortioxetine vs Sertraline in Mexicans

Conditions:   Depression;   Type 2 Diabetes Mellitus
Interventions:   Drug: Vortioxetine;   Drug: Sertraline
Sponsor:   Universidad Juárez Autónoma de Tabasco
Completed

Dapagliflozin Effects on Epicardial Fat

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Metformin
Sponsor:   University of Miami
Active, not recruiting

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Conditions:   Type 2 Diabetes Mellitus;   Proteinuria
Interventions:   Drug: Dipeptidyl Peptidase 4 Inhibitor;   Drug: Sulfonylurea
Sponsor:   Changhua Christian Hospital
Completed

A Clinical Trial of Overweight/Obesity With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Overweight and Obesity
Interventions:   Dietary Supplement: Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance;   Dietary Supplement: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance
Sponsors:   Peking Union Medical College Hospital;   Hebei Dongfangyun Health Management Co.,Ltd
Not yet recruiting

Bexagliflozin Efficacy and Safety Trial (BEST)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Active, not recruiting

Simplified Insulin Regimen for the Elderly

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Glargine;   Drug: Insulin Aspart;   Drug: Insulin Lispro
Sponsor:   University of Miami
Recruiting

Effect of Efpeglenatide on Cardiovascular Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide (SAR439977);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Not yet recruiting

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor;   Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sponsor:   Boehringer Ingelheim
Active, not recruiting

A Study of LY3305677 in Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY3305677;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Active, not recruiting

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Tirzepatide;   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Completed

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: PF-06882961
Sponsor:   Pfizer
Not yet recruiting

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and Women

Conditions:   Diabetes Mellitus, Type 2;   Insulin Resistance;   Menopause;   Hiv
Intervention:  
Sponsors:   University of Witwatersrand, South Africa;   Medical Research Council, South Africa;   GlaxoSmithKline;   University of Oxford;   University Hospital, Umeå
Completed

An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.

Conditions:   Diabetes Mellitus, Type 2;   Skeletal Muscle Insulin Sensitivity
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Insulin glargine U100
Sponsor:   Novo Nordisk A/S
Recruiting

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Insulin Glargine
Sponsor:   Novo Nordisk A/S
Recruiting

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster-acting insulin aspart;   Drug: basal insulin
Sponsor:   Novo Nordisk A/S
Completed

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulphonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Active, not recruiting

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Insulin aspart;   Drug: Insulin glargine U100
Sponsor:   Novo Nordisk A/S
Recruiting

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: exenatide
Sponsor:   Novo Nordisk A/S
Completed

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Sodium Glucose Transporter 2 inhibitor;   Drug: Dipeptidyl-peptidase 4 inhibitor;   Drug: Glucagon-like peptide 1 agonist
Sponsor:   Boehringer Ingelheim
Not yet recruiting

Serum Ferritin and Hepicidin Concentration in Chronic Periodontitis Patients With T2DM

Conditions:   Periodontitis;   Type2 Diabetes
Intervention:  
Sponsor:   Fayoum University
Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

Liraglutide Effects on Epicardial Fat Inflammatory Genes

Conditions:   Type2 Diabetes;   Coronary Artery Disease
Interventions:   Drug: Liraglutide Pen Injector [Victoza];   Drug: matching liraglutide-placebo pre-filled pens
Sponsor:   University of Miami
Recruiting

Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus

Condition:   Type2 Diabetes
Intervention:   Drug: Basalin to Lantus
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting

Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Diagnostic Test: Oral Glucose tolerance test
Sponsors:   Yale University;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

A Phase IV Study in Drug-Naive Patients With T2DM in China

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Acarbose
Sponsor:   AstraZeneca
Recruiting

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Condition:   Pharmacological Action
Interventions:   Drug: Sitagliptin 100mg;   Other: Placebo arm
Sponsors:   Profil Institut für Stoffwechselforschung GmbH;   Merck Sharp & Dohme Corp.
Enrolling by invitation

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: semaglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting

Comparative Effectiveness of Empagliflozin in the US

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: DPP-4 inhibitor
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Fulacimstat (BAY1142524);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide 0.5 mg;   Drug: Semaglutide 1.0 mg;   Drug: Sitagliptin placebo;   Drug: Sitagliptin;   Drug: Semaglutide placebo 0.5 mg;   Drug: Semaglutide placebo 1.0 mg
Sponsor:   Novo Nordisk A/S
Completed

The VA Diabetes Trial Follow-up Study (VADT-FS)

Conditions:   Diabetes;   Glycemic Control
Intervention:  
Sponsor:   VA Office of Research and Development
Completed

The Metformin - Microbiota Study

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Metformin
Sponsors:   Umeå University;   Göteborg University;   Örebro University;   Linkoeping University;   Lunds University;   Karolinska Institutet
Recruiting

Latinos Understanding the Need for Adherence in Diabetes

Conditions:   Type 2 Diabetes;   Glycemic Control;   Cardiovascular Risk Factors;   Psychological Distress
Intervention:   Behavioral: Special Intervention
Sponsor:   San Diego State University
Completed

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors
Sponsor:   Boehringer Ingelheim
Recruiting

"Effect of High Fat and High Glycemic Diets

Condition:   Type 2 Diabetes
Interventions:   Behavioral: High Glycemic Diet;   Behavioral: Control diet
Sponsor:   Mayo Clinic
Active, not recruiting

Semaglutide Treatment On Coronary Progression

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Interventions:   Drug: Semaglutide 2 MG/1.5 ML Subcutaneous Solution;   Drug: Placebo
Sponsor:   Los Angeles Biomedical Research Institute
Recruiting

XIGDUO Extended Release (XR) Post Marketing Surveillance

Condition:   Adult Patients With Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting

The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients

Conditions:   Type 2 Diabetes Mellitus;   Insulin Sensitivity/Resistance
Intervention:   Behavioral: Combined aerobic and strength exercise
Sponsors:   VU University Medical Center;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Completed

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Conditions:   Type2 Diabetes;   Peripheral Neuropathy
Intervention:  
Sponsor:   John Slevin
Recruiting

Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission

Conditions:   Newly Diagnosed Type 2 Diabetes;   Simplified Short-term Intensive Insulin Therapy;   Glycemic Remission
Interventions:   Drug: Simplified intensive insulin therapy regimen;   Drug: Traditional Short-term Intensive insulin therapy
Sponsor:   Sun Yat-sen University
Not yet recruiting

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Orange Juice And Sugar Intervention Study

Conditions:   Cardiovascular Risk Factor;   Type2 Diabetes Mellitus;   Insulin Sensitivity;   Metabolic Syndrome
Interventions:   Other: Naturally-sweetened orange juice;   Other: Sugar-sweetened beverage
Sponsors:   University of California, Davis;   Touro University, California
Recruiting

A Cohort Study of Weight Loss and Gliosis

Condition:   Obesity, Gliosis, Weight-Loss
Interventions:   Behavioral: Behavioral Weight Loss Program;   Procedure: Roux-en-Y Gastric Bypass
Sponsor:   University of Washington
Recruiting

Criticality Analysis of Diabetic Gait Within a Primary Care Pediatric Clinic for Obese Children (PAIDOS)

Condition:   Childhood Obesity
Intervention:   Diagnostic Test: Gait analysis
Sponsors:   Dr Salvador Villalpando-Carrion;   Oxford Brookes University
Enrolling by invitation

Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy

Condition:   Type 2 Diabetes
Intervention:   Device: Rotating Magnetic Therapy
Sponsor:   Majianhua
Not yet recruiting

Empaglifozin in Early Diabetic Kidney Disease

Conditions:   Diabetic Kidney Disease;   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

Condition:   Type2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Completed

Absolute Bioavailability Study With Bexagliflozin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Withdrawn

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Digoxin
Sponsor:   Theracos
Completed

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Exenatide Injection
Sponsor:   Theracos
Completed

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Probenecid;   Drug: Rifampin;   Drug: Verapamil
Sponsor:   Theracos
Completed

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Metformin;   Drug: Glimepiride;   Drug: Sitagliptin
Sponsor:   Theracos
Completed

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Completed

Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Chinese herbal medicine;   Drug: Placebo
Sponsors:   Shanghai University of Traditional Chinese Medicine;   Longhua Hospital;   Shanghai Putuo District Center Hospital
Completed

A Study of LY2922470 in Healthy Participants and Participants With Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: LY2922470
Sponsor:   Eli Lilly and Company
Completed

Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation

Condition:   Pre Diabetes
Interventions:   Other: DNA-based dietary intervention;   Other: DNA-based dietary intervention using an app;   Other: Control arm
Sponsors:   Imperial College London;   DnaNudge Ltd
Recruiting

Outcomes of Laparoscopic Sleeve Gastrectomy

Conditions:   Bariatric Surgery Candidate;   Laparoscopic Sleeve Gastrectomy;   Obesity, Morbid
Intervention:   Procedure: Laparoscopic sleeve gastrectomy
Sponsor:   Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Completed

Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin

Conditions:   Beta-Thalassemia;   Insulin Resistance;   PreDiabetes;   Diabetes Mellitus, Type 2
Intervention:   Other: Resistance exercise
Sponsor:   University of Thessaly
Recruiting

Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)

Condition:   Diabetic Neuropathic Pain
Intervention:   Genetic: Identification of genetic causes of diabetic neuropathic pain
Sponsors:   University of Dundee;   Wellcome Trust;   Diabetes UK
Recruiting

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes

Conditions:   Prediabetic State;   Insulin Resistance
Interventions:   Combination Product: Linagliptin + metformin;   Drug: Metformin
Sponsors:   Universidad de Guanajuato;   Hospital Regional de Alta Especialidad del Bajio
Active, not recruiting

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

Conditions:   Obesity;   Bariatric Surgery;   Morbid Obesity;   Diabetes Mellitus Type 2;   Diet Therapy
Interventions:   Other: Roux-en-Y Gastric Bypass;   Other: Caloric Restriction
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities

Conditions:   Type2 Diabetes;   PreDiabetes
Intervention:   Behavioral: Peer Support Integrated with Primary Care
Sponsors:   Shanghai 6th People's Hospital;   University of North Carolina, Chapel Hill;   Merck Foundation
Not yet recruiting

An Extension Study of PEAK Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: alogliptin+pioglitazone;   Drug: alogliptin;   Drug: pioglitazone
Sponsors:   Kun-Ho Yoon;   Takeda
Terminated

Urinary Vitamin C Loss in Diabetic Subjects

Conditions:   Diabetes Type 1;   Diabetes Type 2;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

Condition:   Diabetes Mellitus in Pregnancy
Interventions:   Behavioral: SweetMama Focus Groups;   Behavioral: SweetMama Individual Testing;   Behavioral: SweetMama Feasibility Testing - Pilot Randomized Trial
Sponsor:   Northwestern University
Recruiting

Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses

Conditions:   Hypoglycemia;   Inflammatory Response;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Procedure: hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
Sponsors:   Radboud University;   Rigshospitalet, Denmark
Not yet recruiting

Diabetes Risk Education and Communication Trial

Conditions:   PreDiabetes;   Diabetes Mellitus;   Diabetes Mellitus, Type 2;   Body Weight;   Body Weight Changes
Interventions:   Behavioral: DiRECT;   Behavioral: Usual care (UC)
Sponsors:   Northwestern University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Condition:   Cushing Syndrome
Interventions:   Drug: Relacorilant;   Other: Placebo
Sponsor:   Corcept Therapeutics
Recruiting

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

Condition:   Safety and Tolerability of EGT0001474 in Healthy Volunteers
Interventions:   Drug: EGT0001474;   Drug: Placebo
Sponsor:   Theracos
Completed

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Adverse Metabolic Effects of Dietary Sugar

Conditions:   Chronic Disease of Cardiovascular System;   Type 2 Diabetes;   Obesity
Interventions:   Other: high fructose corn syrup;   Other: aspartame;   Other: Energy-balanced diet;   Other: Ad libitum diet
Sponsors:   University of California, Davis;   Touro University, California;   University of Southern California;   USDA, Western Human Nutrition Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Effect of FGM on Glucose Control in Diabetic Patients

Condition:   Diabetes Mellitus
Intervention:   Device: Freestyle Libre Flash Glucose Monitoring
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting

Sucrose-sweetened Beverage in African-American and Caucasian Women.

Condition:   Healthy
Intervention:   Dietary Supplement: Sugar-sweetened beverage
Sponsors:   University of California, Davis;   National Institutes of Health (NIH);   Office of Research on Women's Health (ORWH);   National Center for Advancing Translational Science (NCATS);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide 2 MG;   Drug: Dapagliflozin 10 MG
Sponsor:   Consano Clinical Research, LLC
Not yet recruiting

DHS MIND Metabolomics

Condition:   Diabetes
Intervention:  
Sponsors:   Wake Forest University Health Sciences;   National Institute on Aging (NIA)
Not yet recruiting

Insulin Regulation of Lipolysis and Lipolysis Proteins

Condition:   Obesity
Interventions:   Behavioral: Immediate weight loss;   Drug: Pioglitazone;   Behavioral: Deferred weight loss;   Drug: Placebo
Sponsors:   Mayo Clinic;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System

Condition:   Diabetes Mellitus
Intervention:   Device: Onyx BG Meter / App System
Sponsor:   Ascensia Diabetes Care
Completed

DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome

Condition:   Polycystic Ovary Syndrome
Intervention:   Other: Women with polycystic ovary syndrome
Sponsors:   University of Birmingham;   University Hospital Birmingham NHS Foundation Trust;   Birmingham Women's and Children's NHS Foundation Trust;   University Hospital of Wales;   University Hospitals Coventry and Warwickshire NHS Trust;   Royal Infirmary of Edinburgh;   The Leeds Teaching Hospitals NHS Trust;   St Mary's NHS Trust;   Barts & The London NHS Trust
Not yet recruiting

Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

Conditions:   Acute Coronary Syndrome;   Unstable Angina;   Diabetes Mellitus;   Metformin Adverse Reaction
Intervention:   Drug: Metformin
Sponsor:   University of Saskatchewan
Not yet recruiting

Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents

Condition:   Pediatric Obesity
Intervention:   Other: Palmitate Diet
Sponsor:   Yale University
Recruiting

Culturally-Adapted Diet for Puerto Rican Adults

Conditions:   Diabetes Mellitus, Type 2;   Obesity;   Hypertension;   Dyslipidemias;   High Triglycerides;   High Blood Glucose;   Abdominal Obesity
Interventions:   Behavioral: Culturally tailored food and diet advice;   Behavioral: Standard healthy eating advice
Sponsors:   Harvard School of Public Health;   FDI Clinical Research
Not yet recruiting

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

Tolerability and Risk of Adverse Events With a Probiotic Supplement

Condition:   Healthy Individuals
Interventions:   Dietary Supplement: Placebo;   Dietary Supplement: High dose F. prausnitzii and D. piger;   Dietary Supplement: Low dose F. prausnitzii and D. piger
Sponsors:   Sahlgrenska University Hospital, Sweden;   Metabogen AB
Active, not recruiting

Northern Manhattan Study of Metabolism and Mind

Conditions:   Diabetes;   Pre-diabetes;   Cognition - Other;   Depressive Symptoms;   Metabolic Syndrome
Intervention:  
Sponsors:   Columbia University;   National Institute on Minority Health and Health Disparities (NIMHD)
Recruiting

Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients

Condition:   Diabetes
Interventions:   Other: ACP Living with Diabetes Guide;   Other: ADA Living Well with Diabetes Workbook
Sponsors:   University of Arkansas;   Northwestern University;   Louisiana State University Health Sciences Center Shreveport;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors

Condition:   PreDiabetes
Interventions:   Behavioral: Early Time-Restricted Feeding;   Behavioral: Mid-day Time-Restricted Feeding;   Behavioral: Control Schedule
Sponsor:   University of Alabama at Birmingham
Not yet recruiting

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Conditions:   Weight Loss;   Obesity
Interventions:   Drug: Byetta (exenatide);   Behavioral: Weight loss;   Other: Metabolic Chamber;   Drug: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Conditions:   PreDiabetes;   Prehypertension
Interventions:   Drug: Dapagliflozin;   Drug: Placebo - Cap
Sponsor:   University of Guadalajara
Active, not recruiting

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Condition:   Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions:   Drug: DAPA/MET XR;   Drug: DAPA;   Drug: MET XR
Sponsors:   Woman's;   AstraZeneca
Completed

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

Condition:   T2DM With NAFLD
Interventions:   Drug: AZD4076;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting

Impact of Perinatal Exposure to Non-caloric Sweeteners on Food Preferences and Weight Gain in the First Year of Life

Condition:   Exposures Associated With Pregnancy, Delivery and Lactation
Intervention:  
Sponsors:   University of Chile;   University of Concepcion, Chile;   Comisión Nacional de Investigación Científica y Tecnológica
Not yet recruiting

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
Recruiting

Effect of Time-Restricted Feeding on Fat Loss and Cardiometabolic Risk Factors in Overweight Adults

Condition:   Obesity
Interventions:   Behavioral: Early Time-Restricted Feeding;   Behavioral: Control Schedule;   Behavioral: Structured Weight Loss Program
Sponsor:   University of Alabama at Birmingham
Recruiting

Revisional Bariatric Surgery Experience

Conditions:   Bariatric Surgery;   Revisional Bariatric Surgery;   Obesity Associated Disorder
Interventions:   Other: Laparoscopic mini gastric by-pass;   Other: LaparoscopicRe-sleeve gastrectomy;   Other: Laparoscopic Roux-en-Ygastric bypass
Sponsor:   Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Completed

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Conditions:   Heart Failure;   Type II; Diabetes
Interventions:   Drug: Empagliflozin;   Drug: Placebo Oral Capsule
Sponsors:   Yale University;   Boehringer Ingelheim
Completed

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Condition:   Alzheimer Disease
Interventions:   Drug: 18F-MK-6240;   Drug: 11C-PIB
Sponsors:   José A. Luchsinger;   Albert Einstein College of Medicine;   George Washington University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation

Metabolic Responses to Bariatric Surgery

Condition:   Morbid Obesity
Intervention:   Other: Surgery
Sponsor:   University of California, Davis
Recruiting

CharacterIzation of Adult Onset Autoimmune Diabetes

Condition:   Diabetes
Interventions:   Other: Mixed Meal Test;   Other: Dual Energy X-Ray Absorptiometry (DEXA);   Procedure: Adipose Tissue Biopsy
Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
Not yet recruiting

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Condition:   SIADH
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   University Hospital, Basel, Switzerland
Completed

Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation

Conditions:   Head and Neck Cancer;   Oral Cavity Squamous Cell Carcinoma
Intervention:   Drug: Metformin
Sponsors:   University Hospital Inselspital, Berne;   University of Bern;   Werner und Hedy Berger-Janser – Stiftung
Recruiting

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

Condition:   Diabetic Foot
Interventions:   Drug: BAY1193397;   Drug: Placebo
Sponsor:   Bayer
Recruiting

Bariatric Surgery and LDL Cholesterol

Condition:   Bariatric Surgery
Interventions:   Procedure: Gastric bypass;   Procedure: Sleeve gastrectomy
Sponsor:   Parc de Salut Mar
Not yet recruiting

Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy

Condition:   Obesity
Intervention:   Diagnostic Test: NASHMIR
Sponsors:   Diafir;   Clinact
Not yet recruiting

The Effect of a Perinatal Health Promotion Program on the Different Levels of Gestational Hyperglycemic Women

Condition:   Gestational Diabetes
Intervention:   Behavioral: Perinatal health promotion program and regular prenatal care
Sponsor:   Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

Condition:   Obesity
Intervention:   Device: VeSTAL
Sponsors:   Neurovalens Ltd.;   University of California, San Diego;   University of Ulster;   Exploristics
Not yet recruiting